Skip to main content

NEW YORK (TheStreet) -- Shares of stem cell therapy developer Neuralstem  (CUR) - Get Neuralstem, Inc. Report rose 4.62% to $2.72 on higher-than-average volume in afternoon trading Wednesday in sympathy with peer company Brainstorm Cell Therapeutics  (BCLI) - Get Brainstorm Cell Therapeutics Inc. Report .

Brainstorm intends to release the final results from its Phase 2a trial of its stem cell therapy NurOwn on Monday. The company describes NurOwn as an "autologous, adult stem cell therapy technology" designed to treat ALS, also known as Lou Gehrig's Disease.

The company will host a conference call on Monday to discuss the results.

Exclusive Report:Jim Cramer’s Best Stocks for 2015

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

"We are very excited to share the final results of this study," said Brainstorm's CEO Tony Fiorino, MD, PhD, in a company statement. "Professor Karussis presented a very positive and well-received interim analysis of this study at the Joint Congress of European Neurology in June 2014, and the final results include data from several additional subjects and analyses conducted by our independent statisticians."

TheStreet Recommends

"The interim analysis of this study, and results of our prior phase 1/2 study, have shown that a single dose of NurOwn™ is safe and can provide clinically meaningful benefits to ALS patients, such as a reduction in the rate of progression, and in some patients, actual improvements in function," Fiorino continued. "The final results will extend these findings and allow us to move forward with a presentation and publication strategy so that we may share these important data with our medical and scientific colleagues."

More than 1.6 million shares had changed hands as of 12:38 p.m., compared to the daily average volume of 515,673.

Image placeholder title

CUR

data by

YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.